BUZZ-Lexicon surges on licensing deal with Novo Nordisk for obesity drug

Reuters03-28

** Shares of drug developer Lexicon Pharmaceuticals LXRX.O jump 108% to 72 cents premarket

** LXRX says it has entered into an agreement with Novo Nordisk NOVOb.CO to license its non-incretin based experimental drug for obesity and associated metabolic disorders

** Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory and sales milestone payments

** Novo Nordisk will hold an exclusive, worldwide license to develop, manufacture and commercialize the drug candidate, LX9851

** LXRX is eligible to receive tiered royalties on net sales of LX9851

** Up to last close, LXRX stock down 84% in the past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment